Sandwall will join WntResearch as CEO, a biotechnology company active in cancer therapies development. The search for her successor has already started.

“In her ten years at InDex, Pernilla has successfully built up a highly qualified and effective development organisation, which ensures that the work to take the drug candidate cobitolimod through phase III will continue according to plan. Phase III is the final stage of development before application for market approval. I want to direct a warm thanks to Pernilla for an excellent collaboration and wish her all the bestin her next assignment,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.

“It is with mixed emotions that I have decided to accept the offer of a CEO position. I am very proud to have contributed to the development of InDex and I strongly believe in the potential of the company and cobitolimod. The phase III study CONCLUDE is up and running and I am convinced the team will complete it in the best possible way,” said Pernilla Sandwall.